Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.49 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.49 |
| ▸ | PI4KA | P42356 | 1/20 | 0.49 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14475037 | 0.88 | MEN1 (0.59) | PIK3CAPIK3CDPIP5K1CPI4KAPI4KB | |
| SCHEMBL14475050 | 0.87 | CYP1A2 (0.54) | PIK3CAPIK3CDPIP5K1CPI4KAPI4KB | |
| SCHEMBL14475029 | 0.87 | PDE5A (0.51) | PIK3CAPIK3CDPIP5K1CPI4KAPI4KB | |
| SCHEMBL14475072 | 0.86 | MAP4K4 (0.53) | PIK3CAPIK3CDPIP5K1CPI4KAPI4KB | |
| SCHEMBL14474998 | 0.86 | ABCG2 (0.55) | PIK3CAPIK3CDPIP5K1CPI4KAPI4KB | |
| SCHEMBL18023076 | 0.85 | POLB (0.49) | PIK3CAPIK3CDPIP5K1CPI4KAPI4KB | |
| SCHEMBL14474980 | 0.84 | ABCG2 (0.62) | CYP1A2CYP3A4CLK4CYP2D6CYP2C9 | |
| SCHEMBL14475003 | 0.84 | CYP11B2 (0.56) | ADORA2AADORA1CYP1A2CYP3A4CLK4 | |
| SCHEMBL14475063 | 0.83 | RAB9A (0.55) | ADORA2AADORA1CYP1A2CYP3A4CLK4 | |
| SCHEMBL14727837 | 0.83 | ABCG2 (0.56) | ADORA2AADORA1CYP1A2CYP3A4CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| EP-3056207-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2016-08-17 | — | — | EP | disclosed |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | GALENEA CORPORATION | 2015-10-29 | — | — | US | disclosed |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | GALENEA CORPORATION | 2015-10-29 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL COMPANY (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL COMPANY (JP) | 2013-02-28 | — | — | US | disclosed |
| WO-2013003586-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | PIK3CA 1211/4885PIK3CD 728/4885PIP5K1C 577/4885 |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PPP3CB, PTPRG | PIK3CA 1402/4885PIK3CD 764/4885PIP5K1C 914/4885 |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | PIK3CA 1211/4885PIK3CD 728/4885PIP5K1C 577/4885 |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP2CA, PPP4C, PPP3CB | PIK3CA 2052/4885PIK3CD 1559/4885PIP5K1C 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.